SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria: 1. Histologically confirmed diagnosis of B-cell NHL such as DLBCL, FL and MCL 2. Patients received at least 2 lines of systemic therapy 3. Previously received anti- CD20 treatment 4. Patients in stage II should also be unsuitable or unwilling to receive allogeneic hematopoietic stem cell transplantation 5. Patients must have an acceptable organ function Exclusion Criteria: 1. Previously treated with PI3K inhibitors or BTK inhibitors 2. Unresolved toxicity of CTCAE grade \> 1 from prior anti-lymphoma therapy 3. Chemotherapy or other investigational therapy within 28 days (or 5 times the half-life time, whichever is shorter) before starting cycle 1 4. Significant concurrent medical disease or condition which according to the investigators' judgement 5. Active hepatitis B, C or HIV infection 6. Infection requiring treatment 2 weeks prior to the first dosing